What's Happening?
The FDA has issued an Emergency Use Authorization (EUA) for Ivomec (ivermectin) 1% Injection, a preventative treatment for New World Screwworm (NWS) in cattle, developed by Boehringer Ingelheim. This decision was made due to the lack of adequate, approved
alternatives. The EUA allows the use of Ivomec within 24 hours of birth, during castrations, and when wounds appear. The authorization aims to protect animal health, safeguard the food supply, and support cattle producers. The New World Screwworm poses a significant threat to livestock, particularly as it has been reported close to the U.S.-Mexico border.
Why It's Important?
The authorization of Ivomec is crucial for the U.S. cattle industry, as it provides a necessary tool to combat the New World Screwworm, a pest that can severely impact livestock health and productivity. The screwworm's proximity to the U.S. border raises concerns about potential outbreaks, which could disrupt the cattle industry and affect the food supply chain. By enabling preventive measures, the FDA's decision supports cattle producers and veterinarians in managing this threat, thereby protecting economic interests and ensuring the stability of the livestock sector.
What's Next?
The EUA for Ivomec will remain in effect as long as the circumstances justifying its emergency use persist. The USDA and other stakeholders are likely to continue monitoring the screwworm's spread and may implement additional measures to prevent its entry into the U.S. Livestock producers and veterinarians will need to stay informed about best practices for using Ivomec and other preventive strategies to protect their herds.
